IPP Bureau
Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions
By IPP Bureau - October 31, 2025
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
RestorixHealth acquires CutisCare to expands wound care portfolio
By IPP Bureau - October 31, 2025
Lupin Digital Health launches VITALYFE
By IPP Bureau - October 31, 2025
AI-powered cardiometabolic wellness platform for India’s workforce
NATCO launches Everolimus tablets, 1 mg
By IPP Bureau - October 31, 2025
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
By IPP Bureau - October 30, 2025
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Granules India’s facility secures FDA EIR with 'VAI’
By IPP Bureau - October 30, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
By IPP Bureau - October 30, 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
By IPP Bureau - October 30, 2025
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test
By IPP Bureau - October 30, 2025
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
By IPP Bureau - October 30, 2025
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis
By IPP Bureau - October 30, 2025
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery
By IPP Bureau - October 30, 2025
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus
By IPP Bureau - October 30, 2025
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM
By IPP Bureau - October 30, 2025
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
